Skip to main content
INAB
NASDAQ Life Sciences

IN8bio Secures $20.1M Private Placement, Extends Runway, Reports Positive Glioblastoma Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.951
Mkt Cap
$18.653M
52W Low
$1.17
52W High
$7.62
52W Position info
67% above low
Off High info
74% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

INAB sits 67% above its 52-week low of $1.17 on light trading volume (0.2× avg).

Summary

IN8bio announced its Q4 and full-year 2025 financial results, highlighting a significant private placement that extends its cash runway into the first half of 2027, alongside positive clinical data for its glioblastoma programs.


Key Events · Financing and Capital Events · INAB

  • Significant Private Placement

    The company closed an initial $20.1 million tranche of a private placement, with potential for an additional $20.1 million, substantially strengthening its balance sheet.

  • Extended Cash Runway

    Net proceeds of $18.5 million from the private placement are expected to extend the company's cash runway into the first half of 2027, addressing immediate liquidity concerns.

  • Positive Glioblastoma Clinical Data

    Updated data from Phase 1 and 2 trials showed durable survival improvements in newly diagnosed glioblastoma, with repeat dosing nearly doubling median progression-free survival to 13.0 months.

  • Reduced Net Loss

    The company reported a narrowed net loss of $4.9 million for Q4 2025 and a 36% reduction in full-year net loss for 2025 compared to the prior year.


Analysis · INAB · Life Sciences

This 8-K provides crucial updates on IN8bio's financial health and clinical progress, directly addressing the company's ability to continue operations. The initial $20.1 million tranche of a private placement, representing a substantial capital infusion relative to the company's market capitalization, extends the cash runway into the first half of 2027. This financing is critical, especially in light of the concurrent 10-K filing which disclosed a substantial doubt about the company's going concern beyond April 2027. Additionally, the company reported positive updated clinical data for its glioblastoma programs, demonstrating durable survival improvements, which could be a significant value driver. Investors should monitor the company's progress on its clinical milestones and its ability to secure the additional $20.1 million from the private placement.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INAB was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $1.17 to $7.62. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INAB - Latest Insights

INAB
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.820
Real-time Price: $0.750 info
Change: -$0.070 (-9%) info
Market Cap: $8.193M info
INAB
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.840
Real-time Price: $0.750 info
Change: -$0.090 (-11%) info
Market Cap: $8.193M info
INAB
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.9888
Real-time Price: $0.750 info
Change: -$0.2388 (-24%) info
Market Cap: $8.193M info
INAB
Jul 09, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.750 info
Change: -$0.640 (-46%) info
Market Cap: $8.193M info
INAB
Jun 01, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.93
Real-time Price: $0.750 info
Change: -$1.18 (-61%) info
Market Cap: $8.193M info